Trial Profile
A Randomised, Phase IIa Treatment Delayed-start Trial of the Oral JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult Idiopathic Inflammatory Myopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Myositis
- Focus Therapeutic Use
- Acronyms MYOJAK
- 17 Oct 2023 Status changed from active, no longer recruiting to completed.
- 17 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 17 Apr 2023 Planned End Date changed from 31 Oct 2023 to 25 Sep 2023.